Resistance Trend, Antibiotic Utilization and Mortality in Patients with E. coli Bacteraemia by Najmi, Amirreza et al.
 
Open Access Maced J Med Sci electronic publication ahead of print,  
published on April 14, 2019 as https://doi.org/10.3889/oamjms.2019.223 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci.                                                                                                                                                                                                          1 
 
ID Design Press, Skopje, Republic of Macedonia 
Open Access Macedonian Journal of Medical Sciences. 
https://doi.org/10.3889/oamjms.2019.223 
eISSN: 1857-9655 
Clinical Science 
 
 
  
 
Resistance Trend, Antibiotic Utilization and Mortality in Patients 
with E. coli Bacteraemia 
 
 
 
Amirreza Najmi
1
, Fateme Karimi
1
, Vijayanarayan Kunhikatta
1
, Muralidhar Varma
2
, Sreedharan Nair
1*
 
 
1
Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, 
Manipal, Karnataka, India; 
2
Department of Medicine, Kasturba Medical College, Manipal Academy of Higher Education, 
Manipal, Karnataka, India 
 
Citation: Najmi A, Karimi F, Kunhikatta V, Varma M, Nair 
S. Resistance Trend, Antibiotic Utilization and Mortality in 
Patients with E. coli Bacteraemia. Open Access Maced J 
Med Sci. https://doi.org/10.3889/oamjms.2019.223 
Keywords: Resistance pattern; E. coli; ESBL producing; 
Empirical therapy; Rational antibiotic use; Mortality 
*Correspondence: Sreedharan Nair. Department of 
Pharmacy Practice, Manipal College of Pharmaceutical 
Sciences, Manipal Academy of Higher Education, 
Manipal, Karnataka. E-mail: nair.sreedhar@manipal.edu 
Received: 28-Jan-2019; Revised: 18-Mar-2019; 
Accepted: 19-Mar-2019; Online first: 14-Apr-2019 
Copyright: © 2019 Amirreza Najmi, Fateme Karimi, 
Vijayanarayan Kunhikatta, Muralidhar Varma, Sreedharan 
Nair. This is an open-access article distributed under the 
terms of the Creative Commons Attribution-
NonCommercial 4.0 International License (CC BY-NC 4.0) 
Funding: This research did not receive any financial 
support 
Competing Interests: The authors have declared that no 
competing interests exist 
 
 
 
 
 
 
Abstract 
BACKGROUND: Incidence of bacteraemia and driving concerns about antibiotic resistance is increasing globally. 
Risk factors for developing antimicrobial resistance are antibiotic overuse, incorrect dosing and extended duration 
of administration.  
AIM: This study was conducted to examine the prescription and susceptibility pattern of antibiotics in bacteraemia 
patients with ESBL producing and Non-ESBL-producing E. coli and their correlation with mortality.  
METHODS: Data were collected from medical records of the patients aged 18 years and above, diagnosed with 
E. coli bacteremia from January 2013 through July 2017. Institutional ethics committee approval was obtained 
before the study (IEC 483/2017). Cumulative sensitivity/resistance pattern of isolated microorganisms and 
DDD/100 bed days of prescribed antibiotics were obtained.  
RESULTS: 182 cases of E. coli bacteraemia were reviewed. 59.9% (n = 109) were male with an age range of 20-
90 years. The mortality rate was 24.9% (n = 44). 55.5% (n = 101) of the isolated organisms were ESBL-
producing. A high percentage of resistance to cephalosporins and fluoroquinolones were observed among the 
patients, and most of the identified isolates were sensitive to the aminoglycosides, carbapenems and β-lactam 
and β-lactamase inhibitor combinations (BLBLIs). 
CONCLUSIONS: Frequent utilisation of the high-end antibiotics and increase in microorganism’s resistance to 
different antibiotics can lead to a worrisome level. Local antibiotic resistance data and consumption policy are 
essential to prevent and slow down this process. We observed a descending resistance trend for amoxicillin-
clavulanic acid combination in our setting to both the ESBL producing and non-producing. 
 
 
 
 
 
 
 
Introduction 
 
Antibiotic resistance can be considered as 
one of the most critical public health issues in the 
world [1]. There are different risk factors for 
developing antimicrobial resistance. Antibiotic 
overuse, incorrect dosing and extended duration of 
administration can be among the most important ones 
[1], [2], [3], [4]. We observe a more challenging 
situation in less developed countries.
 
In several 
studies, the inappropriate antimicrobial prescription 
was observed among the primary care physicians [5], 
[6], [7], [8] and development of bacterial resistance 
increases the challenges faced by the physicians to 
treat the patients [9], [10], [11]. 
Pathogenic Escherichia coli (E. coli) can 
cause serious diseases, such as urinary tract 
infections(UTIs) and bacteraemia [12], [13], [14], and 
incidence of bacteraemia increasing globally [15]. 
Bacteria which can usually develop the more serious 
disease is ESBL (Extended-spectrum β-lactamases) 
producing E. coli. ESBLs are enzymes that can 
hydrolyse penicillins, aztreonam and cephalosporin’s 
[16]. These ESBL producing bacteria showed lesser 
acceptable clinical outcome in comparison to 
susceptible (non-ESBL producing bacteria) bacteria 
[17], [18], [19], [21], which can be related to delay in 
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appropriate antimicrobial treatment to some extent 
[22], [23], [24]. The high rate of clinical successes was 
observed in existing literature with carbapenems 
administration for ESBL producing bacteria [25], [26], 
[27], [28]. On the other hand, the use of 
Cephalosporins [29] and β-lactam–β-lactamase 
inhibitor combinations [28], [30] have also been 
suggested recently with ESBL-positive isolates if MICs 
are below clinical breakpoints. Moderate to high in 
vitro activity of piperacillin-tazobactam (PTZ) against 
ESBLs is suggested by several studies [31], [32], [33]. 
Equivalence between PTZ and carbapenems in the 
treatment of ESBL infection was demonstrated in 
some studies [17]. 
This study was conducted to examine the 
prescription and susceptibility pattern of antibiotics in 
bacteraemia patients with ESBL producing and Non-
ESBL-producing E. coli and their correlation with 
mortality. Based on the above background, this study 
focus on the resistance trend, antibiotic utilisation and 
mortality in patients with E. coli bacteraemia. 
 
 
Material and Methods 
 
In this cross-sectional study, we reviewed 
data obtained from 182 patients aged 18 years and 
above who had experienced bloodstream infection 
with E. coli during five years from Jan 2013 through 
Dec 2017. The Institutional Ethics Committee 
approval (IEC 483/2017) was obtained before the start 
of the study.  
Bacteremia was defined as the presence of 
viable bacteria in the bloodstream [34]. Patients were 
excluded if the presence of E. coli was not confirmed 
by blood culture testing and through microbiology 
laboratory report. Antibiotic sensitivity results were 
obtained from the patient medical record [35]. 
The culture reports and antibiotic resistance 
pattern were extracted from online microbiology lab 
reports database and information on antibiotic 
prescription from the patient’s records. The DDD/100 
bed days was calculated for the antibiotics by using 
the AMC tools software.  
The data was analysed by SPSS 20.0 
software.  
 
 
Results 
 
Of the 182 patients who met the inclusion 
criteria, 59.9% (n = 109) of the patients were male, 
with age range from 20 to 90 years. The mortality rate 
was 24.9% (n = 44), and mortality rates trends over 
time are displayed in Figure 1.  
 
Figure 1: Mortality rate in patients with different types of E.coli 
isolates over time 
 
The isolated organisms were 55.5% (n = 101) 
ESBL-producing E. coli, and the rest of the organisms 
were at least sensitive to 4
th
 generation 
cephalosporins. 
Antibiotic sensitivities among the total patient 
population, viz patients with ESBL producing E. coli, 
patients with non-ESBL producing E. coli represented 
in Table 1.  
Table 1: Resistance pattern of different E. coli isolates 
Antibiotic name Non-ESBL 
producing E. coli 
resistance (%) 
ESBL producing 
E. coli 
resistance (%) 
All E. coli 
species 
resistance (%) 
Amikacin 1.3 10.9 6.1 
Ampicilin/amoxicillin 77.6 100 90.2 
Cefotaxime/ceftriaxone 55.8 100 80.9 
Cefuroxime 68.4 100 85.6 
Cefazolin/cefadroxil 45.5 100 82.4 
Cefpirome/cefepime 2.0 100 68 
Ciprofloxacin 55.1 95 77.5 
Amoxicillin-clavulanic-acid 24.7 93.1 55.6 
Trimethoprim-sulphametoxazole 41.6 54.5 48.9 
Gentamicin 21.8 50.5 38 
Netilmicin 0.0 18.2 12.1 
Imipenem 4.3 6.9 6.1 
Piperacillin-tazobactam 8.5 29.7 23 
Cefoperazone-sulbactam 2.1 22.8 16.2 
Colistin 0 0 0 
 
Among the patients with non-ESBL producing 
E. coli, 45 (55.8%) had an organism resistant to 
cefotaxime. Sensitivity to the colistin, imipenem, 
amikacin and netilmicin were observed in most of the 
ESBL enzyme producing as well as non-producing E. 
coli species. Utilisation pattern of antibiotics in terms 
of DDD/100 bed-days is depicted in Figure 2.  
 
Figure 2: Antibiotic utilisation pattern of patients with E. coli 
bloodstream infections over time 
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A group of 40.7% (n = 74) were treated with a 
cefoperazone-sulbactam combination, and 36.8% (n = 
67) were treated with a piperacillin-tazobactam 
combination and were the most frequently 
administered antibiotics. 
Sixty-two patients (34.1%) received 
ceftriaxone as empirical therapy. A group of 83.9% (n 
= 52) of these patients stopped receiving ceftriaxone 
before the full course of the antibiotic was completed 
and 35.5% (n = 22) of these patients received a single 
dose of ceftriaxone after their admission to the 
hospital. The trend in the change of antibiotic 
resistance is shown in Figure 3. 
 
Figure 3: Resistant trends of E. coli isolates to different antibiotics 
over time 
 
 
 
Discussion 
 
ESBL enzyme producing species were 
dominant in this study, while a lower ratio was 
reported in other studies [36], [37]. Resistance among 
E. coli species to a variety of antibiotics is increasing. 
A prior study suggested the use of Ceftriaxone as 
empirical therapy [29], while we observed an 
increasing trend of resistance to ceftriaxone among all 
the reviewed E. coli isolates. More than one-third of 
the patients received ceftriaxone as antimicrobial 
therapy, and most of them received under-dose 
medication. This could have affected the increment of 
cephalosporin’s resistance, revealing that added 
antimicrobial administration control policy may help to 
overcome antimicrobial resistance.  
ESBL producing E. coli species were 93.1% 
susceptible to carbapenems/imipenem which is 
supported by other studies [25], [26], [27], [28]. A 
group of 78.2% and 71.3 sensitivity was observed to 
the cefoperazone-sulbactam and piperacillin-
tazobactam combinations respectively which is 
supported by other studies as well [28], [30]. 
Aminoglycosides were found to be effective against 
the entire reviewed E. coli isolates. Netilmicin can be 
recommended as a superior antimicrobial over 
gentamicin based on its similar activity and higher 
safety. 
The most frequently prescribed antibiotics 
were cefoperazone-sulbactam, meropenem and 
piperacillin-tazobactam respectively. Comparison of 
the DDD/100 bed days results with the trend in 
resistance pattern of antibiotics over time revealed 
that a greater number of antibiotics administered in a 
specific year, more resistance was observed in the 
same or next year. The behaviour of the resistance 
pattern of organisms to antibiotics such as amoxicillin-
clavulanic acid, cefepime-cefoperazone-sulbactam 
and piperacillin-tazobactam can support this claim. 
The mortality rate of the patients with ESBL 
producing E. coli bloodstream infection was higher in 
comparison with non-ESBL producing E. coli 
infections, and it supports the prior studies [17], [18], 
[19], [20], [21]. The difference in the mortality rate of 
the ESBL producing and non-ESBL producing 
organisms has constantly been increasing from 2013, 
and this can reflect the increase in the ineffectiveness 
of antimicrobial therapy on resistant organism over 
time. 
E. coli infection is the most prevalent 
bloodstream infection in our study population. Most of 
these patients received 3
rd
 gen. cephalosporins 
empirical therapy and treatment usually continue with 
a β-lactam and β-lactamase inhibitor combination or 
carbapenems after releasing of culture sensitivity 
reports. Due to the high resistance of these isolates to 
cephalosporins, more appropriate empirical therapy 
can be selected. ESBL enzyme producing species are 
the most serious bacterial infection, and they should 
be treated according to evidence-based culture 
reports. The ability to identify patients at risk for 
resistant organisms has important implications. 
Therefore, an appropriate empirical therapy according 
to local resistance pattern database should be 
selected. 
We observed a descending resistance trend 
for amoxicillin-clavulanic acid combination in our 
setting to both the ESBL producing and non-producing 
E. coli isolates, and its use as empirical therapy for 
bloodstream infections by E. coli organism. Despite 
high utilisation of cefoperazone-sulbactam, 
piperacillin-tazobactam and meropenem in our 
patients, the organisms still show a reliable sensitivity 
toward these antibiotics as shown in the figure3, and 
this can support the recommendation of other studies 
for their utilisation [28], [30]. 
After all, we should express that the 
pathogenic microorganisms are getting more 
susceptible to the older and rarely prescribed 
antibiotics. Local constantly updated microorganism’s 
resistant data is essential in every hospital and must 
be prepared and used in antimicrobial treatment 
guidelines to improve the empirical therapies. 
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